Zhao J, Wu N, Zhang S C, Zhao Z W, Li L J, Liu J T
Department of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital/National Clinical Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer/Key Laboratory of Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.
Department of Cancer Prevention Center, Tianjin Medical University Cancer Institute and Hospital/National Clinical Center for Cancer/Key Laboratory of Cancer Prevention and Therapy, Tianjin/Tianjin's Clinical Research Center for Cancer/Key Laboratory of Prevention and Therapy, Tianjin Medical University, Ministry of Education, Tianjin 300060, China.
Zhonghua Zhong Liu Za Zhi. 2020 May 23;42(5):353-361. doi: 10.3760/cma.j.cn112152-112152-20190919-00614.
Breast cancer is a kind of malignant tumor which seriously endangers women's health. With the development of molecular biology technology and the further understanding of pathogenesis, the treatment of breast cancer has entered a new era of molecular targeted therapy, and has been making new progress. At present, molecular targeted drugs for the treatment of breast cancer keep emerging, mainly including endocrine therapy targeting estrogen and progesterone receptor (ER/PR), targeted drugs treatment for epidermal growth factor receptor-2 (HER-2); phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway inhibitors, anti-angiogenic drugs, poly (ADP-ribose) polymerase (PARP) inhibitors for BRCA1/2 mutations, cyclin-dependent kinases (CDK) 4/6 inhibitors, etc. Because some signal pathway abnormalities may occur in different molecular types of breast cancer, the same targeted drugs are cross-used in different types.
乳腺癌是一种严重危害女性健康的恶性肿瘤。随着分子生物学技术的发展以及对发病机制的进一步认识,乳腺癌的治疗已进入分子靶向治疗的新时代,并不断取得新进展。目前,用于治疗乳腺癌的分子靶向药物不断涌现,主要包括针对雌激素和孕激素受体(ER/PR)的内分泌治疗、针对表皮生长因子受体-2(HER-2)的靶向药物治疗;磷脂酰肌醇3激酶(PI3K)/蛋白激酶B(Akt)/哺乳动物雷帕霉素靶蛋白(mTOR)通路抑制剂、抗血管生成药物、用于BRCA1/2突变的聚(ADP-核糖)聚合酶(PARP)抑制剂、细胞周期蛋白依赖性激酶(CDK)4/6抑制剂等。由于不同分子类型的乳腺癌可能会出现一些信号通路异常,相同的靶向药物在不同类型中交叉使用。